Clinical Trials Browser

Phase 2 × Myeloproliferative Disorders × ibrutinib × Clear all

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Phase 2 Active not recruiting

LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders